摘要
Hepatocellular carcinoma(HCC)is a common malignancy and an important cause of cancer death worldwide.Chronic hepatitis B virus(HBV)infection is the major cause of HCC.Recent studies of HBV-induced carcinogenesis not only discovered many new biomarkers but also developed a novel theory:Cancer Evolution-Development(Cancer Evo-Dev).Cancer Evo-Dev provides an evolutionary insight of developing more reasonable predictive and prognostic strategies.Characterizing chronic inflammatory microenvironment of cancer evolution,genetic polymorphisms of inflammatory factors,and HCC-related HBV mutations that negatively selected by host immunity may help greatly in identifying HBV-infected individuals who are more likely to develop HCC or benefit from HCC prophylactic options.Gene expression signatures and somatic mutation profiles reflect the different patterns of signaling pathway networks underlying tumor heterogeneity and can be applied to improve the molecular classification and prognostic stratification of HCC patients.Mutant cells that survive the selection can retro-differentiate into tumor initial cells and aggressive sub-clones.Detection of mutants or their hallmarks in cell-free DNA in peripheral blood potentially improve the early diagnosis,prognosis prediction,and personalized treatment of HBV-caused HCC.
基金
supported by grants from the National Key Basic Research Program(Grant No.2015CB554006).